Report Overview

The UK Angelman Syndrome Therapeutics market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The Angelman syndrome (AS) is a rare genetic and neurological disorder characterized by severe developmental delay and learning disabilities; absence or near absence of speech; inability to coordinate voluntary movements (ataxia); tremulousness with jerky movements of the arms and legs and a distinct behavioral pattern characterized by a happy disposition and unprovoked episodes of laughter and smiling. Angelman syndrome is caused by one of several different types of disruptions of a region of Chromosome 15, all involving a single gene, UBE3A. Although those with the syndrome may be unable to speak, many gradually learn to communicate through other means such as gesturing. Some children with Angelman syndrome may have distinctive facial features but most facial features reflect the normal parental traits.

The Angelman syndrome affects males and females in equal numbers. The prevalence of Angelman syndrome is estimated to be approximately 1 in 12,000-20,000 people in the whole population. However, many cases may go undiagnosed making it difficult to determine the disorders prevalence accurately. Angelman syndrome is not a degenerative disease. Children with Angelman syndrome can expect a normal lifespan.



Market Growth Drivers

The Angelman syndrome treatment market is expected to grow over the forecast period, due to increasing research activities and R&D expenditure. Government initiatives in developing new treatment options for Angelman syndrome are expected to drive the growth of the UK Angelman syndrome treatment market over the forecast period 2020-2028.

Furthermore, the effectiveness of the treatment by reducing the effect of the symptoms is also driving the UK Angelman syndrome treatment market growth. Improvements in the healthcare sector are further facilitating the growth of the Angelman syndrome treatment market over the forecast period.

Market Restraints

However, rising treatment costs, lack of awareness among patients and physicians & low diagnosis rate because of difficulty in diagnosis about Angelman Syndrome will be the major factors acting as restraints over the forecast period.